---
schema_version: "secwatch.filing_event.v1"
accession: "0001145197-23-000047"
form_type: "8-K"
ticker: "PODD"
cik: "0001145197"
company_name: "INSULET CORP"
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:38:26.173485+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Insulet extends Amgen supply agreement through 2028, adds IP license

## Summary
- Amendment 21 extends term to December 31, 2028; parties to negotiate renewal by Jan 1, 2027.
- Insulet and Amgen entered a Patent Assignment and License Agreement for IP rights.
- New manufacturing site(s) added; Insulet responsible for equipment/labor to maintain quality.
- Minimum purchase commitments revised but specific amounts redacted.
- Payment terms amended; Safety Agreement terminated.

## SEC filing metadata
- accession: 0001145197-23-000047
- form_type: 8-K
- ticker: PODD
- cik: 0001145197
- company_name: INSULET CORP
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000047/0001145197-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000047/podd-20230601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001145197-23-000047
- JSON: https://secwatch.observer/filing/0001145197-23-000047.json
- Plain text: https://secwatch.observer/filing/0001145197-23-000047.txt

## Key facts
- Material Agreements
  INSULET CORP amended Amendment Number 21 with Amgen Inc. (effective 2023-06-01).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Amgen Inc.
  - Effective: 2023-06-01
  source text: On June 1, 2023, Insulet Corporation (the “ Company ”) and Amgen Inc. (“ Amgen ”) entered into Amendment Number 21 (“ Amendment 21 ”) to the Supply Agreement, dated as of November 21, 2013, between the Company and Amgen, as amended by Amendments 1-20, pursuant to which Insulet manufactures and sells to Amgen customized devices (the “ Original Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000047/0001145197-23-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.